Team Category: Clinical Team
Liz Darlison, MBE
Liz has enjoyed 40 years of clinical practice at the University Hospitals of Leicester (UHL). After brief spells in vascular surgery and coronary care Liz spent a decade in UHL’s very research active respiratory unit. This led to an interest in service developments, research and lung cancer which became the focus for the last 24 years of her clinical practice. In response to patient need in 2004, Liz established Mesothelioma UK, a national charity for mesothelioma.
Currently she is a Consultant Nurse at UHL and is also CEO at Mesothelioma UK. Liz has Honorary university positions in both Leicester and Sheffield, is very research active, keenly promotes nursing as a career and engages in education and training on many levels.
Liz is a founder member of the International Thoracic Oncology Nurses Forum, a past chair, and now lifetime honorary member, of Lung Cancer Nursing UK, a long serving previous board member of The British Thoracic Oncology Group and a current, first nurse member of the International Mesothelioma Interest Group board.
In the 2019 Queen Elizabeth’s Birthday honours list, Liz was invited to become a Member of the British Empire (MBE) in recognition of her services to patients and cancer research.
Tasneem Khalifa
Clare Belcher
Molly Scotland
Research Nurse – Hope Trials Facility, Leicester Royal Infirmary from 2017 to present. Chemotherapy Nurse – Chemotherapy Suite, Leicester Royal Infirmary 2013- 2017 Staff Nurse – Renal Transplant Unit, Leicester General Hospital 2013
Dr. Sean Dulloo
Dean Fennell, FRCP, PhD
Professor Dean Fennell is a clinician scientist and international leader in mesothelioma research. He has designed and led several investigator-initiated trials from phase 1 through phase III including the first precision medicine platform study for patients with mesothelioma (MIST).
He is past-president of the International mesothelioma interest group, past NCRI mesothelioma chair, co-author of UK BTS, and European (ESMO, ERS) mesothelioma treatment guidelines and served two terms on the EORTC board. His lab is currently pioneering novel precision medicine strategies and the study of tumour evolution in mesothelioma.
Professor Fennell held two CRUK clinician scientist and MRC doctoral fellowships. He originally trained in pharmacology (1st class) and medicine at UCL , then completed training in London. Prof. Fennell has published 167 peer reviewed articles in journals including The Lancet, Lancet Oncology, New England Journal of Medicine, Nature, & Nature communications
In 2023 he was awarded the IMIG Senior Investigator medal and MARF Pioneer Award for his work in the field.